Welcome to the UPF Digital Repository

Assessing the impact of COVID-19 on liver cancer management (CERO-19)

Show simple item record

dc.contributor.author Muñoz Martínez, Sergio
dc.contributor.author Coll Estrada, Susanna
dc.contributor.author Reig, María
dc.date.accessioned 2021-06-22T06:52:31Z
dc.date.available 2021-06-22T06:52:31Z
dc.date.issued 2021
dc.identifier.citation Muñoz-Martínez S, Sapena V, Forner A, Nault JC, Sapisochin G, Rimassa L et al. Assessing the impact of COVID-19 on liver cancer management (CERO-19). JHEP Rep. 2021;3(3):100260. DOI: 10.1016/j.jhepr.2021.100260
dc.identifier.issn 2589-5559
dc.identifier.uri http://hdl.handle.net/10230/47958
dc.description.abstract Background & aims: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems and it may have heavily impacted patients with liver cancer (LC). Herein, we evaluated whether the schedule of LC screening or procedures has been interrupted or delayed because of the COVID-19 pandemic. Methods: An international survey evaluated the impact of the COVID-19 pandemic on clinical practice and clinical trials from March 2020 to June 2020, as the first phase of a multicentre, international, and observational project. The focus was on patients with hepatocellular carcinoma or intrahepatic cholangiocarcinoma, cared for around the world during the first COVID-19 pandemic wave. Results: Ninety-one centres expressed interest to participate and 76 were included in the analysis, from Europe, South America, North America, Asia, and Africa (73.7%, 17.1%, 5.3%, 2.6%, and 1.3% per continent, respectively). Eighty-seven percent of the centres modified their clinical practice: 40.8% the diagnostic procedures, 80.9% the screening programme, 50% cancelled curative and/or palliative treatments for LC, and 41.7% modified the liver transplantation programme. Forty-five out of 69 (65.2%) centres in which clinical trials were running modified their treatments in that setting, but 58.1% were able to recruit new patients. The phone call service was modified in 51.4% of centres which had this service before the COVID-19 pandemic (n = 19/37). Conclusions: The first wave of the COVID-19 pandemic had a tremendous impact on the routine care of patients with liver cancer. Modifications in screening, diagnostic, and treatment algorithms may have significantly impaired the outcome of patients. Ongoing data collection and future analyses will report the benefits and disadvantages of the strategies implemented, aiding future decision-making. Lay summary: The coronavirus disease 2019 (COVID-19) pandemic has posed unprecedented challenges to healthcare systems globally. Herein, we assessed the impact of the first wave pandemic on patients with liver cancer and found that routine care for these patients has been majorly disrupted, which could have a significant impact on outcomes.
dc.format.mimetype application/pdf
dc.language.iso eng
dc.publisher Elsevier
dc.relation.ispartof JHEP Rep. 2021;3(3):100260
dc.rights © 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver (EASL). This is anopen access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
dc.rights.uri http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.title Assessing the impact of COVID-19 on liver cancer management (CERO-19)
dc.type info:eu-repo/semantics/article
dc.identifier.doi http://dx.doi.org/10.1016/j.jhepr.2021.100260
dc.subject.keyword BCLC, Barcelona Clinic Liver Cancer
dc.subject.keyword CERO-19, Liver Cancer Outcome in the COVID-19-pandemic Project
dc.subject.keyword COVID-19
dc.subject.keyword COVID-19, coronavirus disease 2019
dc.subject.keyword Cholangiocarcinoma
dc.subject.keyword Clinical trials
dc.subject.keyword ENS-CCA, European Network for the Study of Cholangiocarcinoma
dc.subject.keyword HCC, hepatocellular carcinoma
dc.subject.keyword Hepatocellular carcinoma
dc.subject.keyword LC, liver cancer
dc.subject.keyword LT, liver transplantation
dc.subject.keyword Liver cancer
dc.subject.keyword Management
dc.subject.keyword Nurses
dc.subject.keyword SARS-CoV-2, severe acute respiratory syndrome coronavirus-2
dc.subject.keyword iCCA, intrahepatic cholangiocarcinoma
dc.rights.accessRights info:eu-repo/semantics/openAccess
dc.type.version info:eu-repo/semantics/publishedVersion


This item appears in the following Collection(s)

Show simple item record

Search DSpace

Advanced Search


My Account


Compliant to Partaking